J. Brynskov

发表

Letter: persistence of anti‐infliximab antibodies after discontinuation of infliximab in patients with IBD

K. Bendtzen, C. Steenholdt, J. Brynskov, 2012, Alimentary pharmacology & therapeutics.

A phylogenetic group of Escherichia coli associated with active left-sided Inflammatory Bowel Disease

E. Nielsen, A. Petersen, K. Krogfelt, 2009, BMC Microbiology.

Confocal Laser Endomicroscopy in Inflammatory Bowel Disease--A Systematic Review.

Ditlev Nytoft Rasmussen, Peter Vilmann, P. Vilmann, 2015, Journal of Crohn's & colitis.

Confocal laser endomicroscopy: a novel method for prediction of relapse in Crohn’s disease

P. Vilmann, A. Saftoiu, T. Klausen, 2015, Endoscopy.

Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn’s Disease Is Determined by Their Concentration

W. Huisinga, C. Kloft, H. Edlund, 2016, The AAPS Journal.

Commentary: antibodies reacting with the infliximab Fab portion – something new? Authors' reply

K. Bendtzen, C. Nielsen, C. Steenholdt, 2013, Alimentary pharmacology & therapeutics.

Normal ranges and reproducibility for the quantitative Romberg's test

J. Brynskov, H. Thyssen, E. Jansen, 1982, Acta neurologica Scandinavica.

Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics

T. S. Jørgensen, C. Steenholdt, J. Brynskov, 2022, Scandinavian journal of gastroenterology.

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

L. A. Christensen, K. Bendtzen, J. Kjellberg, 2013, Gut.

Cultures of Human Colonic Epithelial Cells Isolated from Endoscopical Biopsies from Patients with Inflammatory Bowel Disease. Effect of IFNγ, TNFα and IL-1β on Viability, Butyrate Oxidation and IL-8 Secretion

K. Bendtzen, J. Brynskov, T. Saermark, 2000 .

Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Experimental cytokine modulation therapy of inflammatory bowel disease (Crohn's disease and ulcerative colitis)

K. Bendtzen, J. Brynskov, J. Hendel, 1996 .

Cyclosporine for induction of remission in Crohn's disease.

D. Jewell, B. Feagan, J. Macdonald, 2005, The Cochrane database of systematic reviews.

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

K. Bendtzen, C. Steenholdt, J. Brynskov, 2016, Inflammatory bowel diseases.

Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis

B. Vainer, O. Nielsen, J. Brynskov, 1996, Digestive Diseases and Sciences.

Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review.

O. Nielsen, K. Bendtzen, J. Brynskov, 1994, Digestive diseases.

Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease.

J. Brynskov, C. Andersen, N. Tvede, 1992, Gut.

Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy

C. Steenholdt, J. Brynskov, O. Thomsen, 2015, The American Journal of Gastroenterology.

Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease.

L. Konge, P. Vilmann, A. Møller, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

K. Bendtzen, C. Nielsen, C. Steenholdt, 2013, Alimentary pharmacology & therapeutics.

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

K. Bendtzen, C. Steenholdt, J. Brynskov, 2009, Scandinavian journal of gastroenterology.

Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin.

J. Brynskov, N. Tvede, 1990, Gut.

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.

S. Vermeire, E. Louis, F. Baert, 2010, Journal of Crohn's & colitis.

Gene expression profiling in autoimmune diseases: Chronic inflammation or disease specific patterns?

L. Hegedüs, K. Bendtzen, C. Nielsen, 2007, Autoimmunity.

Cytokines in inflammatory bowel disease.

O. Nielsen, K. Bendtzen, J. Brynskov, 1992, Scandinavian journal of gastroenterology.

Interleukin-2 receptor alpha and beta chain expression by circulating alpha beta and gamma delta T cells in inflammatory bowel disease.

O. Nielsen, J. Brynskov, I. Kirman, 1995, Digestive diseases and sciences.

Interleukin-2 receptor α and β chain expression by circulating αβ and γδ T cells in inflammatory bowel disease

O. Nielsen, J. Brynskov, I. Kirman, 1995, Digestive Diseases and Sciences.

Topical Rosiglitazone Treatment Improves Ulcerative Colitis by Restoring Peroxisome Proliferator-Activated Receptor-γ Activity

J. Brynskov, G. Pedersen, 2010, The American Journal of Gastroenterology.

Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease

O. Nielsen, E. Langholz, J. Brynskov, 1994, Digestive Diseases and Sciences.

Distinct inflammatory and cytopathic characteristics of Escherichia coli isolates from inflammatory bowel disease patients.

A. Petersen, K. Krogfelt, S. Brix, 2015, International journal of medical microbiology : IJMM.

TNF‐α‐Converting Enzyme Activity in Colonic Biopsy Specimens from Patients with Inflammatory Bowel Disease Revealed by mRNA and in Vitro Assay

J. Brynskov, C. Ellervik, T. Særmark, 1999, Annals of the New York Academy of Sciences.

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

K. Bendtzen, C. Steenholdt, J. Brynskov, 2014, BMJ Open.

Inflammatory bowel disease (ulcerative colitis and Crohn's disease): diagnostic criteria and differential diagnosis.

J. Brynskov, O. Thomsen, P. Fogh, 1998, Drugs of today.

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

K. Bendtzen, C. Steenholdt, J. Brynskov, 2012, Alimentary pharmacology & therapeutics.

Outcome of continued infliximab therapy in Crohn’s disease patients with response but without remission after one year of infliximab – a retrospective cohort study

C. Steenholdt, J. Brynskov, S. Buhl, 2018, Scandinavian journal of gastroenterology.

Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease.

J. Brynskov, S. Rasmussen, 1996, Scandinavian journal of gastroenterology. Supplement.

Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.

W. Sandborn, R. Lorenz, J. Brynskov, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study

C. Steenholdt, J. Brynskov, K. Christensen, 2015, Scandinavian journal of gastroenterology.

Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease

O. Nielsen, K. Bendtzen, M. Coskun, 2016, Medicine.

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease

W. Huisinga, C. Kloft, N. Bolstad, 2020, United European gastroenterology journal.

Identifying and understanding disease burden in patients with inflammatory bowel disease

T. S. Jørgensen, C. Steenholdt, J. Brynskov, 2022, BMJ open gastroenterology.

Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.

K. Bendtzen, M. Svenson, C. Steenholdt, 2012, Journal of Crohn's & colitis.

Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease.

O. Nielsen, K. Bendtzen, J. Brynskov, 1993, Danish medical bulletin.

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

J. Jahnsen, M. Eberhardson, E. Langholz, 2022, Scandinavian journal of gastroenterology.

Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease

K. Bendtzen, C. Steenholdt, J. Brynskov, 2016, Journal of clinical gastroenterology.

Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.

L. A. Christensen, K. Bendtzen, J. Kjeldsen, 2015, Journal of Crohn's & colitis.

Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab

L. A. Christensen, K. Bendtzen, J. Kjellberg, 2015, Digestive Diseases and Sciences.

Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD

K. Bendtzen, C. Steenholdt, J. Brynskov, 2014, Inflammatory bowel diseases.

Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

K. Bendtzen, C. Steenholdt, J. Brynskov, 2014, The American Journal of Gastroenterology.

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

K. Bendtzen, J. Brynskov, M. Ainsworth, 2008, The American Journal of Gastroenterology.

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

J. Seidelin, C. Steenholdt, J. Brynskov, 2012, Scandinavian journal of gastroenterology.

Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn's disease fistulas.

J. Brynskov, T. Saermark, E. Bruun, 2011, Basic & clinical pharmacology & toxicology.

Direct and quantitative vitamin B12 absorption measurement in patients with disorders in the distal part of the bowel

H. Dige-Petersen, J. Brynskov, M. Bayat, 1994, International Journal of Colorectal Disease.

Interleukin‐2 stimulation of blood mononuclear cells from patients with inflammatory bowel disease

J. Brynskov, N. Tvede, 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.

L. A. Christensen, J. Kjeldsen, C. Steenholdt, 2015, Journal of Crohn's & colitis.

Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease

C. Steenholdt, J. Brynskov, O. Thomsen, 2017, Inflammatory bowel diseases.

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

K. Bendtzen, M. Svenson, C. Steenholdt, 2011, Alimentary pharmacology & therapeutics.

A simple filter-paper technique allows detection of mucosal cytokine levelsin vivo in ulcerative colitis

O. Nielsen, J. Brynskov, J. Hendel, 1996, Digestive Diseases and Sciences.

A simple filter-paper technique allows detection of mucosal cytokine levels in vivo in ulcerative colitis. Interleukin-1 and interleukin-1-receptor antagonist.

O. Nielsen, J. Brynskov, J. Hendel, 1996 .

Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population‐based cohort study

N. Uldbjerg, B. Bibby, C. Hvas, 2021, Alimentary pharmacology & therapeutics.

Adhesion molecules in inflammatory and neoplastic intestinal diseases.

O. Nielsen, K. Bendtzen, J. Brynskov, 1995, Digestive diseases.

Quantification of specific E. coli in gut mucosa from Crohn's disease patients.

O. Nielsen, C. Struve, C. Sternberg, 2011, Journal of microbiological methods.

Soluble interleukin-2 receptors in ulcerative colitis

O. Nielsen, J. Brynskov, 1993, Mediators of inflammation.

Inhibitor of interleukin-1α and interleukin-1β-induced T-cell activation in serum of patients with active Crohn's disease

K. Bendtzen, J. Brynskov, C. Reimert, 1991, Digestive Diseases and Sciences.

Cyclosporine in inflammatory bowel disease.

O. B. Schaffalitzky de Muckadell, K. Lauritsen, V. Binder, 1988, Transplantation Proceedings.

Vitamin B12 binding proteins (transcobalamin and haptocorrin) in serum and synovial fluid of patients with rheumatoid arthritis and traumatic synovitis.

P. A. Christensen, J. Brynskov, P. Gimsing, 1983, Scandinavian journal of rheumatology.

afety of Celecoxib in Patients With Ulcerative Colitis in emission : A Randomized , Placebo-Controlled , Pilot Study

R. Lorenz, J. Brynskov, W. Stenson, 2006 .

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response

J. Gisbert, P. Higgins, A. Hart, 2012, Inflammatory bowel diseases.

Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin

K. Bendtzen, E. Langholz, V. Binder, 1992, Alimentary pharmacology & therapeutics.

Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease.

O. B. Schaffalitzky de Muckadell, K. Lauritsen, V. Binder, 1991, Scandinavian journal of gastroenterology.

TREATMENT OF REFRACTORY ULCERATIVE COLITIS WITH CYCLOSPORIN ENEMAS

V. Binder, J. Brynskov, O. Thomsen, 1989, The Lancet.

Herpes Zoster Meningoencephalitis: A Novel, Rare, Potentially Fatal Side Effect to Tofacitinib.

L. Kristensen, C. Steenholdt, J. Brynskov, 2021, The American journal of gastroenterology.

Renographic monitoring of renal function in patients with Crohn's disease treated with low dose cyclosporin: a controlled study.

H. Thomsen, S. L. Nielsen, J. Brynskov, 1990, British medical journal.

Vitamin D and Inflammatory Bowel Disease: Mendelian Randomization Analyses in the Copenhagen Studies and UK Biobank

B. Nordestgaard, J. Brynskov, C. Kobylecki, 2018, The Journal of clinical endocrinology and metabolism.

Cyclosporin for inflammatory bowel disease: mechanisms and possible actions.

J. Brynskov, 1993, Scandinavian journal of gastroenterology.

A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998

D. Jewell, S. Hanauer, G. D'Haens, 2000, Inflammatory bowel diseases.

The role of ciclosporin therapy in Crohn's disease. A review.

J. Brynskov, 1991, Digestive diseases.

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

S N Rasmussen, K. Lauritsen, V. Binder, 1989, The New England journal of medicine.

Low‐dose cyclosporin for Crohn's disease: implications for clinical trials

K. Lauritsen, V. Binder, J. Brynskov, 1989, Alimentary pharmacology & therapeutics.

Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease.

J. Brynskov, J. Kampmann, L. Freund, 1992, Scandinavian Journal of Gastroenterology.

Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls.

T. R. Licht, A. Wilcks, C. Steenholdt, 2012, Beneficial microbes.

Disease-Specific Enteric Microbiome Dysbiosis in Inflammatory Bowel Disease

A. Petersen, K. Krogfelt, J. Brynskov, 2018, Front. Med..

Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease

T. Kirkegaard, J. Brynskov, E. Bruun, 2004, Gut.

Screening for dysplasia and TP53 mutations in closed rectal stumps of patients with ulcerative colitis or Crohn disease

P. Guldberg, V. Binder, J. Brynskov, 2004, Scandinavian journal of gastroenterology.

Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience

J. Brynskov, M. Ainsworth, A. Teisner, 2010, Scandinavian journal of gastroenterology.

This month in Scandinavian Journal of Gastroenterology

J. Brynskov, 2009 .

Biodegradable stents for the treatment of bowel strictures in Crohn's disease: technical results and challenges

P. Vilmann, J. Brynskov, J. Karstensen, 2016, Endoscopy international open.

CIMETIDINE AND ROMBERG'S TEST

J. Brynskov, H. Thyssen, E. Jansen, 1980, The Lancet.

Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.

W. Huisinga, C. Kloft, H. Edlund, 2019, Therapeutic drug monitoring.

Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

K. Bendtzen, N. Bolstad, C. Steenholdt, 2020, Scandinavian journal of gastroenterology.

Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial

J. T. Bjerrum, L. Gluud, J. Brynskov, 2022, EClinicalMedicine.

A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease

K. Schmiegelow, C. Steenholdt, J. Brynskov, 2018, Journal of Crohn's & colitis.

[Determination of vitamin B12 (cobalamine) absorption by means of a simple double-isotope technic. An alternative to Schilling's test].

J. Brynskov, P. Gimsing, K. Hjelt, 1986, Ugeskrift for laeger.

Cobalamin binding proteins (haptocorrin and transcobalamin) in human cerebrospinal fluid.

P. A. Christensen, J. Brynskov, P. Gimsing, 2009, Scandinavian journal of haematology.

Diurnal variations in cobalamin binding plasma proteins.

J. Brynskov, P. Gimsing, 2009, Scandinavian journal of haematology.

Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31.

C. Steenholdt, J. Brynskov, M. Ainsworth, 2012, Journal of Crohn's & colitis.

This month in Scandinavian Journal of Gastroenterology

J. Brynskov, 2011 .

Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease

K. Schmiegelow, C. Steenholdt, J. Brynskov, 2018, Digestive Diseases and Sciences.

Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos).

P. Vilmann, A. Saftoiu, T. Klausen, 2016, Gastrointestinal endoscopy.

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

K. Bendtzen, C. Steenholdt, J. Brynskov, 2011, Scandinavian journal of gastroenterology.

Effect of acetylsalicylic acid on postural stability.

P. A. Christensen, J. Brynskov, H. Thyssen, 1988, Pharmacology & toxicology.

Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease

T. Klausen, K. Bendtzen, C. Steenholdt, 2013, Therapeutic drug monitoring.

Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors’ reply

K. Bendtzen, M. Svenson, C. Steenholdt, 2011 .

Can Measurements of Anti-Infliximab Antibodies Predict Acute Severe Infusion Reactions to Infliximab?

K. Bendtzen, M. Svenson, C. Steenholdt, 2011 .

A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients’ and physicians’ preferences and adherence

C. Steenholdt, J. Brynskov, M. Ainsworth, 2021, Scandinavian journal of gastroenterology.

Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease

N. Bolstad, C. Steenholdt, J. Brynskov, 2021, Therapeutic drug monitoring.

Absence of relationship between CDAI or CRP and infliximab exposure calls for objective Crohn's disease activity measures for the evaluation of treatment effects at treatment failure.

W. Huisinga, C. Kloft, H. Edlund, 2019, Therapeutic drug monitoring.

Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus

T. R. Licht, P. van den Abbeele, T. van de Wiele, 2013, Scientific Reports.

P536 Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease

K. Bendtzen, C. Steenholdt, J. Brynskov, 2014 .

Monitoring immunogenicity of protein-based TNF antagonists

K. Bendtzen, C. Steenholdt, J. Brynskov, 2015, Frontline Gastroenterology.

Alcohol and postural imbalance

J. Brynskov, H. Thyssen, E. Jansen, 1981, Zeitschrift für Rechtsmedizin.

Trajectories of health‐related quality of life and fatigue during vedolizumab therapy in inflammatory bowel disease

C. Steenholdt, J. Brynskov, Ruben Lorentsen, 2022, Journal of gastroenterology and hepatology.

FALSE LOW SERUM VITAMIN B12 VALUES WITH RADIODILUTION ASSAYS USING BLOCKED R-BINDERS

J. Brynskov, P. Gimsing, E. Hippe, 1983, The Lancet.

Expression and function of toll-like receptor 8 and Tollip in colonic epithelial cells from patients with inflammatory bowel disease

L. Andresen, C. Steenholdt, J. Brynskov, 2009, Scandinavian journal of gastroenterology.

Ex vivo intestinal adhesion of Escherichia coli LF82 in Crohn's disease.

O. Nielsen, S. Brix, J. Brynskov, 2011, Microbial pathogenesis.

Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas

J. Fleckner, J. Brynskov, G. Pedersen, 2005, Scandinavian journal of gastroenterology.

Comment on ‘Predicting the response to infliximab from trough serum levels’

K. Bendtzen, C. Steenholdt, J. Brynskov, 2010, Gut.

C. Steenholdt, J. Brynskov, Peter Vilmann, 2021, Clinical Gastroenterology and Hepatology.

Screening for dysplasia in patients with 22–40 years of ulcerative colitis in a population-based cohort from Copenhagen county

T. Horn, V. Binder, J. Brynskov, 2003 .

Fusidic acid for Behçet's colitis: a novel approach to T-cell specific immunosuppressive therapy.

K. Bendtzen, E. Langholz, J. Brynskov, 1991, Danish medical bulletin.

Expression of Toll‐like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium *

J. Rask-Madsen, L. Andresen, J. Brynskov, 2005, Clinical and experimental immunology.

Tofacitinib for acute severe ulcerative colitis: a systematic review.

J. Seidelin, C. Steenholdt, J. Brynskov, 2023, Journal of Crohn's & colitis.

Circulating cytokines and cytokine receptors in infliximab treatment failure due to TNF-independent Crohn disease

C. Steenholdt, J. Brynskov, M. Sine Buhl, 2016 .

Cytokines in inflammatory bowel disease.

O. Nielsen, K. Bendtzen, J. Brynskov, 1992, Scandinavian journal of gastroenterology.

Increased concentrations ofinterleukin 1I3, interleukin-2, andsoluble interleukin-2 receptorsin endoscopical mucosal biopsy specimens withactive inflammatory bowel disease

J. Brynskov, N. Tvede, M. Vilién, 1992 .

ORAL CONTRACEPTIVES AND THE COBALAMIN (VITAMIN B12) METABOLISM

O. Munck, J. Brynskov, K. Hjelt, 1985, Acta obstetricia et gynecologica Scandinavica.

Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease

J. Jahnsen, J. Dahlerup, T. Klausen, 2022, NEJM Evidence.

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

K. Bendtzen, C. Steenholdt, J. Brynskov, 2016, Inflammatory bowel diseases.

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

K. Bendtzen, C. Steenholdt, J. Brynskov, 2009, Scandinavian journal of gastroenterology.

Letter: persistence of anti‐infliximab antibodies after discontinuation of infliximab in patients with IBD

C. Steenholdt, J. Brynskov, Klaus Bendtzen, 2012, Alimentary pharmacology & therapeutics.

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.

S. Vermeire, E. Louis, F. Baert, 2010, Journal of Crohn's & colitis.

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

K. Bendtzen, C. Steenholdt, J. Brynskov, 2011, Scandinavian journal of gastroenterology.

Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.

C. Steenholdt, J. Brynskov, R. Klaasen, 2024, Journal of gastroenterology and hepatology.

INFLUENCE OF RANITIDINE ON POSTURAL STABILITY

J. Brynskov, H. Thyssen, E. Jansen, 1982, The Lancet.

Tofacitinib for acute severe ulcerative colitis: a systematic review.

J. Seidelin, C. Steenholdt, J. Brynskov, 2023, Journal of Crohn's & colitis.

This month in Scandinavian Journal of Gastroenterology

J. Brynskov, 2008 .